About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:ABT
CUSIP00282410
Phone224-667-6100
Debt
Debt-to-Equity Ratio0.67
Current Ratio1.66
Quick Ratio1.24
Price-To-Earnings
Trailing P/E Ratio25.16
Forward P/E Ratio22.00
P/E Growth1.81
Sales & Book Value
Annual Sales$27.39 billion
Price / Sales4.03
Cash Flow$4.7877 per share
Price / Cash13.14
Book Value$17.87 per share
Price / Book3.52
Profitability
EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins1.67%
Return on Equity14.54%
Return on Assets6.34%
Miscellaneous
Employees99,000
Outstanding Shares1,753,190,000
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Friday, June 8th. Shareholders of record on Friday, July 13th will be paid a dividend of $0.28 per share on Wednesday, August 15th. This represents a $1.12 dividend on an annualized basis and a yield of 1.78%. The ex-dividend date of this dividend is Thursday, July 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) released its quarterly earnings data on Wednesday, April, 18th. The healthcare product maker reported $0.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.58 by $0.01. The healthcare product maker had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $7.28 billion. Abbott Laboratories had a net margin of 1.67% and a return on equity of 14.54%. The firm's revenue was up 16.7% on a year-over-year basis. During the same period last year, the company posted $0.48 EPS. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories updated its FY18 earnings guidance on Wednesday, April, 18th. The company provided earnings per share guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.86. Abbott Laboratories also updated its Q2 guidance to $0.70-0.72 EPS.
What price target have analysts set for ABT?
17 Wall Street analysts have issued 12-month target prices for Abbott Laboratories' shares. Their predictions range from $56.00 to $80.00. On average, they expect Abbott Laboratories' stock price to reach $68.4375 in the next year. View Analyst Ratings for Abbott Laboratories.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White, Chairman & CEO (Age 63)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
- Mr. Brian J. Blaser, Exec. VP of Diagnostic Products (Age 53)
- Scott M. Leinenweber, VP of Investor Relations
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)
Has Abbott Laboratories been receiving favorable news coverage?
Headlines about ABT stock have trended somewhat positive on Monday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abbott Laboratories earned a media sentiment score of 0.21 on Accern's scale. They also gave press coverage about the healthcare product maker an impact score of 45.23 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.39%), Massachusetts Financial Services Co. MA (2.28%), Northern Trust Corp (1.49%), Diamond Hill Capital Management Inc. (0.60%), FIL Ltd (0.54%) and Dimensional Fund Advisors LP (0.54%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which major investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Independent Franchise Partners LLP, Massachusetts Financial Services Co. MA, Flossbach Von Storch AG, Coho Partners Ltd., Swiss National Bank, American Century Companies Inc., Northern Trust Corp and Legal & General Group Plc. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which major investors are buying Abbott Laboratories stock?
ABT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Montag & Caldwell LLC, Ceredex Value Advisors LLC, Eaton Vance Management, Summit Trail Advisors LLC, Mackay Shields LLC, CIBC World Markets Inc. and Franklin Resources Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $62.91.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $110.29 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
